Almac Trial Coordinator Launched In $48 Million Investment To Advance Integrated eClinical Technologies

Innovative technology platform reshapes how sponsors, CRO, and clinical sites manage complex clinical trials at scale

Almac Group has today announced a $48 million investment in eClinical technologies that includes the launch of Almac Trial Coordinator™ – a first-in-class interoperable clinical trial technology platform, enhancements to its eClinical ecosystem capabilities, and creation of over 100 advanced technology roles globally. This investment addresses the top technology challenges facing sponsors, CROs, and clinical sites through the solution’s market-disrupting and interoperable approach to integration, enabling high-quality, efficient trials with full visibility, reduced risk, and enhanced patient engagement.  

Almac Trial Coordinator™ is purpose-built to unify operational processes, clinical data, and systems into one unified protocol.  The platform is novel due to its unique ability to meet the industry’s pressing and unmet system fragmentation challenge, offering both standardisation and flexibility where trials and data providers differ. This supports sponsors in futureproofing their technology strategy, eliminates vendor lock-in, and greatly expands the number of sites capable of meeting the demands of modern clinical trials.  

The platform features open APIs and standards-based exports to fit modern tech stacks to ensure interoperability for its users- offering full visibility across connected solutions and supporting fast, low-disruption protocol amendments through controlled workflows. Key usability features include intuitive, role-specific interfaces, two-tap onboarding, 24/7 multilingual support, and built-in localisation and validation. These leading features are all underpinned by strong data provenance and reusable libraries of standardised study templates to accelerate study build and ensure quality.  

“This investment underscores our commitment to delivering flexible, scalable solutions that empower sponsors and sites to run complex trials with confidence and efficiency,” said Valarie Higgins, President & Managing Director at Almac Clinical Technologies.  “Almac Trial Coordinator™ is a transformative solution with a unique focus on streamlining the site’s ability to navigate today’s eClinical ecosystem with confidence and ease- addressing a critical industry need that does not get enough attention.”  

Kees van Ooik, Vice President of eClinical Solutions, added: “Our vision is to simplify complexity and deliver measurable value through an integrated eClinical ecosystem. This investment enables us to enhance interoperability, improve user experience, and meet the evolving needs of global clinical trials.” 

About Almac Group 

Almac Group is a global contract development and manufacturing organization providing a comprehensive range of services across the drug development lifecycle. From R&D and biomarker discovery to clinical trial supply and commercial-scale manufacturing, Almac supports pharmaceutical and biotech companies worldwide. Privately owned and organically grown over five decades, Almac employs over 7,700 professionals across 18 facilities in Europe, the U.S., and Asia. Learn more at almacgroup.com and follow us on LinkedIn. 

About Almac Clinical Technologies 

Almac Clinical Technologies delivers industry-leading clinical trial technology and expertise, supporting sponsors and CROs with its advanced Interactive Response Technology (IRT) and integrated eCOA solutions. With a focus on compliance, precision, and reliability, Almac streamlines site, patient, and supply management while enabling data-driven decisions and global participant engagement.